Vaccine Effectiveness against Symptomatic SARS-CoV-2 Infection in Adults Aged 65 Years and Older in Primary Care: I-MOVE-COVID-19 Project, Europe, December 2020 to May 2021 - Sorbonne Université Access content directly
Journal Articles Eurosurveillance Year : 2021

Vaccine Effectiveness against Symptomatic SARS-CoV-2 Infection in Adults Aged 65 Years and Older in Primary Care: I-MOVE-COVID-19 Project, Europe, December 2020 to May 2021

Esther Kissling
  • Function : Correspondent author
  • PersonId : 1089378

Connectez-vous pour contacter l'auteur
Ruby Tsang
  • Function : Author

Abstract

We measured COVID-19 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection at primary care/outpatient level among adults ≥q 65 years old using a multicentre test-negative design in eight European countries. We included 592 SARS-CoV-2 cases and 4,372 test-negative controls in the main analysis. The VE was 62% (95% CI: 45\textendash 74) for one dose only and 89% (95% CI: 79\textendash 94) for complete vaccination. COVID-19 vaccines provide good protection against COVID-19 presentation at primary care/outpatient level, particularly among fully vaccinated individuals.
Fichier principal
Vignette du fichier
eurosurv-26-29_4.pdf (145.59 Ko) Télécharger le fichier
Origin : Publication funded by an institution
Licence : CC BY - Attribution

Dates and versions

hal-03846535 , version 1 (27-01-2023)

Licence

Attribution

Identifiers

Cite

Esther Kissling, Mariëtte Hooiveld, Virginia Sandonis Martin, Iván Martinez-Baz, Naoma William, et al.. Vaccine Effectiveness against Symptomatic SARS-CoV-2 Infection in Adults Aged 65 Years and Older in Primary Care: I-MOVE-COVID-19 Project, Europe, December 2020 to May 2021. Eurosurveillance, 2021, 26 (29), ⟨10.2807/1560-7917.ES.2021.26.29.2100670⟩. ⟨hal-03846535⟩
56 View
9 Download

Altmetric

Share

Gmail Facebook X LinkedIn More